151 related articles for article (PubMed ID: 20340018)
1. Rituximab as a first-line agent for the treatment of dermatomyositis.
Haroon M; Devlin J
Rheumatol Int; 2012 Jun; 32(6):1783-4. PubMed ID: 20340018
[TBL] [Abstract][Full Text] [Related]
2. Rituximab and mycophenolate combination therapy in refractory dermatomyositis with multiple autoimmune disorders.
Parziale N; Kovacs SC; Thomas CB; Srinivasan J
J Clin Neuromuscul Dis; 2011 Dec; 13(2):63-7. PubMed ID: 22361690
[TBL] [Abstract][Full Text] [Related]
3. MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report.
Alqatari S; Riddell P; Harney S; Henry M; Murphy G
BMC Pulm Med; 2018 Apr; 18(1):59. PubMed ID: 29665800
[TBL] [Abstract][Full Text] [Related]
4. Erythroderma and extensive poikiloderma - a rare initial presentation of dermatomyositis: a case report.
Herath HMMTB; Keragala BSDP; Pahalagamage SP; Janappriya GHCC; Kulatunga A; Gunasekera CN
J Med Case Rep; 2018 Mar; 12(1):83. PubMed ID: 29571300
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy].
García Hernández FJ; Chinchilla Palomares E; Castillo Palma MJ; González Pulido C; Ocaña Medina C; Sánchez Román J
Med Clin (Barc); 2010 Jul; 135(6):256-9. PubMed ID: 20537666
[TBL] [Abstract][Full Text] [Related]
6. [Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab: report of one case].
Yáñez V J; Cisternas M M; Saldías H V; Saldías P F
Rev Med Chil; 2009 Jan; 137(1):88-93. PubMed ID: 19399327
[TBL] [Abstract][Full Text] [Related]
7. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
8. Rituximab as therapy for refractory polymyositis and dermatomyositis.
Noss EH; Hausner-Sypek DL; Weinblatt ME
J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
Oddis CV; Reed AM; Aggarwal R; Rider LG; Ascherman DP; Levesque MC; Barohn RJ; Feldman BM; Harris-Love MO; Koontz DC; Fertig N; Kelley SS; Pryber SL; Miller FW; Rockette HE;
Arthritis Rheum; 2013 Feb; 65(2):314-24. PubMed ID: 23124935
[TBL] [Abstract][Full Text] [Related]
11. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in the treatment of refractory dermatomyositis.
Chiappetta N; Steier J; Gruber B
J Clin Rheumatol; 2005 Oct; 11(5):264-6. PubMed ID: 16357773
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review.
Borges IBP; Silva MG; Misse RG; Shinjo SK
Rheumatol Int; 2018 Feb; 38(2):293-301. PubMed ID: 29027009
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of rituximab in refractory antisynthetase syndrome.
Limaye V; Hissaria P; Liew CL; Koszyka B
Intern Med J; 2012 Mar; 42(3):e4-7. PubMed ID: 22432998
[TBL] [Abstract][Full Text] [Related]
16. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
[TBL] [Abstract][Full Text] [Related]
17. [Two cases of acute progressive interstitial pneumonia associated with dermatomyositis--clinical features and immunological disorders].
Okuda Y; Takasugi K; Imai A; Oyama T; Oyama H
Ryumachi; 1993 Aug; 33(4):293-301. PubMed ID: 8235910
[TBL] [Abstract][Full Text] [Related]
18. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
Muñoz-Beamud F; Isenberg DA
Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin-induced dermatomyositis.
Oztas M; Ugurlu S; Aydin O
Rheumatol Int; 2017 Jul; 37(7):1217-1219. PubMed ID: 28238074
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.
Cooper MA; Willingham DL; Brown DE; French AR; Shih FF; White AJ
Arthritis Rheum; 2007 Sep; 56(9):3107-11. PubMed ID: 17763414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
